FDA approves Neuronetics’ transcranial magnetic stimulation treatment for depression-related anxiety

The FDA has approved Neuronetics’ transcranial magnetic stimulation system as a treatment for adults with major depressive disorder, the company said this week.

Advertisement

“Presentation of anxiety symptoms in patients with [major depressive disorder] is typically more complex to successfully treat with currently available medications,” Melissa Fickey, MD, founder of Embracing Life Wellness Center, said in a news  release from Neuronetics.

The company tested its NeuroStar advanced therapy for mental health device on 664 patients diagnosed with major depressive disorder and found 65.5 percent of them showed a clinically meaningful response to the treatment.

In May, the FDA approved Neuronetics’ device for adjunct treatment of adults with obsessive compulsive disorder.

Advertisement

Next Up in Behavioral Health Technology

  • Transcranial magnetic stimulation, vagus nerve stimulation and deep brain stimulation are reshaping how clinicians treat complex mood and neuropsychiatric disorders.

  • New Hyde Park, N.Y.-based Northwell Health held a grand opening for its $5 million, 12,000-square-foot Behavioral Health Wellness Center in…

Advertisement

Comments are closed.